Research Specifications
- IUPAC Name:
- Tirzepatide (LY3298176)
- CAS Number:
- 2023788-19-2
- Molecular Weight:
- 4813.5 Da
- Side Chain:
- C20 fatty diacid (enables albumin binding, once-weekly dosing)
- Form:
- Lyophilized powder
- Purity:
- ≥98% (HPLC verified)
- Storage:
- −20°C long-term / 4°C up to 4 weeks reconstituted
- Price per mg:
- $9.33
GLP-2 T 30mg
Dual GLP-1/GIP receptor agonist. SURMOUNT-1 trial: 22.5% mean body weight reduction at 15mg — the first approved dual incretin.
−22.5%
Mean Weight Reduction
SURMOUNT-1, 15mg (NEJM 2022)
2 receptors
Simultaneous Targets
GLP-1 + GIP
4813 Da
Molecular Weight
NCBI PubChem
Receptor Targets
Dual Incretin Agonism: GLP-1 & GIP Receptors
Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide with a C20 fatty diacid side-chain that enables once-weekly dosing via albumin binding. It simultaneously activates GLP-1 receptors (reducing appetite, slowing gastric emptying, improving insulin sensitivity) and GIP receptors (enhancing glucose-stimulated insulin secretion and promoting adipocyte lipolysis). This dual mechanism outperforms GLP-1 monotherapy in head-to-head trials. It lacks the glucagon receptor component of Retatrutide, making it a 'step 2' rather than 'step 3' in the receptor-targeting progression.
Research Highlights
SURMOUNT-1 Trial (NEJM 2022)
2,539 participants across 72 weeks. The 15mg dose group achieved 22.5% mean body weight reduction vs 2.4% placebo. 37% of participants achieved ≥25% weight loss. The trial also demonstrated significant improvements in waist circumference, blood pressure, lipids, and fasting glucose — a comprehensive cardiometabolic profile.
GIP Receptor Advantage Over Semaglutide
Direct comparison trial (SURPASS-2) showed Tirzepatide 15mg produced 5.5% greater weight loss than Semaglutide 1mg at 40 weeks. The additional GIP agonism drives adipocyte-level lipolysis and may improve insulin secretion more effectively in high-fat dietary contexts.
Body Composition
SURMOUNT body composition sub-analysis showed the majority of weight loss was from fat mass, with lean mass preserved at a higher percentage than caloric restriction alone — consistent with GIP's hypothesized role in adipose-specific energy mobilization.
Research FAQ
What is the difference between Tirzepatide and Semaglutide?
How does Tirzepatide compare to Retatrutide?
What is the 30mg vial pricing per mg?
What is the C20 fatty diacid modification on Tirzepatide?
Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.
Price Comparison
| Supplier | Purity | Price | Shipping |
|---|---|---|---|
| Apollo (via ClavTides) | >98% HPLC | $279.99 | Free over $200 |
| Generic Research Suppliers | Varies (often <95%) | Similar–Higher | Varies |
| Pharmaceutical (Rx only) | Pharmaceutical grade | Not available for research | Rx required |
Related Products
GLP-2 T 15mg
Tirzepatide is a synthetic multi-receptor peptide analog consisting of 39 amino acids with lipidation to enhance stability. Supplied as a lyophilized powder for laboratory research applications.
GLP-2 T 60mg
Tirzepatide is a synthetic multi-receptor peptide analog consisting of 39 amino acids with lipidation to enhance stability. Supplied as a lyophilized powder for laboratory research applications.
GLP-2 T 15mg (4 pack)
4-pack bundle of Tirzepatide 15mg. Synthetic multi-receptor peptide analog supplied as lyophilized powder for laboratory research applications.
GLP-2 T 30mg
$279.99